Sweden combines scientific quality with one of Europe’s most connected healthcare and research systems.
With a population of 10.6 million and nearly 9,900 studies listing at least one Swedish site on ClinicalTrials.gov, the country has built substantial clinical research depth relative to its population.
Stockholm, Uppsala, Gothenburg, Lund, Malmö, Linköping and Umeå form the core of the research landscape, anchored by institutions such as Karolinska University Hospital, Uppsala University Hospital and Sahlgrenska University Hospital.
For sponsors, Sweden’s value goes beyond investigator quality.
A nationally coordinated healthcare structure, established health registries and strong academic research centres can support patient feasibility, long term follow up and registry informed research where appropriate approvals and governance are in place.
Sweden is also building practical infrastructure for more decentralized study models. Electronic consent, remote data collection and distributed study processes can reduce dependence on repeated hospital visits and create more flexible participation pathways.
This makes Sweden particularly relevant for programs requiring specialist investigators, longitudinal data, complex patient follow up and research across oncology, cardiovascular medicine, neuroscience, metabolic disease and other evidence intensive therapeutic areas.